Prof Matthias Götberg (Interventional Cardiologist at Skane University Hospital, Lund, SE) provides an overview of the recent two-year data presented from the SCAAR registry and an overview of the bifurcation subset analysis that was presented at EuroPCR in May 2025.

Prof Götberg is a contributor to The Swedish Coronary Angiography and Angioplasty Registry (SCAAR), he discusses the key findings from the data, describes insights into how DCBs are used in real world patients and supports the use of DCB in hybrid procedures for complex PCI.

Watch the video to learn more about the SCAAR data, the bifurcation sub analysis and the different findings from the two-year data.

Learn More About Prevail

Low Event Rates in Bifurcations With Prevail™ DCB

* The event rates are based on KM estimates
Source: Von Koch, S. et al. A paclitaxel-balloon compared with contemporary drug-coated balloons for bifurcation lesions and Götberg. et al. How do I confidently expand my DCB practice. Presented at EuroPCR 2025

Low TLR Rates and 0% Definite Thrombosis in Bifurcations With Prevail™ DCB

Source: Götberg. et al. How do I confidently expand my DCB practice. Presented at EuroPCR 2025

23% of SCAAR Patients Had Bifurcation Lesions

Hybrid^† PCI (DCB and a stent) was a prevalent treatment option

§ Do not treat the same lesion segment with more than one Prevail DCB.
† Warning: Drug-eluting stents must not be implanted into the vessel segment that has been treated with a Prevail DCB

Source: Von Koch, S. et al. A paclitaxel-balloon compared with contemporary drug-coated balloons for bifurcation lesions . Presented at EuroPCR 2025
 

Key Takeaways

• In bifurcation lesions, Prevail™ DCB demonstrated low mortality and revascularisation rates : 0% target lesion definite thrombosis¹, 2.3% new MI, and 2.8% TLR at 1 year²
• In bifurcations treated with a hybrid PCI^† approach, Prevail™ DCB showed excellent results with 0.4% new MI and 0.7% TLR at 1 year²
• Prevail™ DCB is now approved for the treatment of bifurcation lesions³, supported by the bifurcation subgroup analysis from SCAAR²
• DCBs play an important role in bifurcation PCI: simplifying the procedure, potentially reducing the number of stents and promoting positive vessel remodeling⁴
   

† Warning: Drug-eluting stents must not be implanted into the vessel segment that has been treated with a Prevail DCB
1 Götberg. et al. How do I confidently expand my DCB practice. Presented at EuroPCR 2025
2 Von Koch, S. et al. A paclitaxel-balloon compared with contemporary drug-coated balloons for bifurcation lesions and Götberg. et al. How do I confidently expand my DCB practice. Presented at EuroPCR 2025
3 Medtronic data on file 
4 Raban V. Jeger et al. J Am Coll Cardiol Intv 2020; 13:1391-1402

For distribution only in markets where the Prevail™ paclitaxel-coated PTCA balloon catheter and expanded indications have been approved. Not for distribution in the USA, France, Japan, or Canada. Prevail™ DCB expanded indications are approved in EU and UK.